ofloxacin has been researched along with Recrudescence in 79 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections." | 9.10 | [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003) |
| "In a prospective randomized study ofloxacin (400 mg orally once daily) versus co-trimoxazole (320/1,600 mg orally once daily) were given for 3 weeks in 30 and 22 elderly semimobile patients respectively, suffering from asymptomatic bacteriuria." | 9.07 | Kinetics and comparative efficacy of ofloxacin versus co-trimoxazole in the asymptomatic bacteriuria of elderly subjects. ( Dontas, A; Giamarellou, H; Iakovou, M; Petrikkos, G; Pistoni, M; Sfikakis, P, 1991) |
| "In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)." | 9.07 | Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. ( Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991) |
| " The objective is to determine the effect of application of topical ofloxacin on nasal and sinus mucosa in patients with proven existence of bacterial biofilms and persistent chronic sinusitis after FESS." | 7.81 | Effect of topical ofloxacin on bacterial biofilms in refractory post-sinus surgery rhino-sinusitis. ( Ezzat, WF; Fawaz, SA; Hamdy, TA; Rabie, H; Shokry, YA, 2015) |
| "It has been shown previously that fluoroquinolone resistance (defined by resistance to at least 2 mg/liter ofloxacin) has a different impact on moxifloxacin monotherapy depending on the mutation in the sole fluoroquinolone target in Mycobacterium tuberculosis, i." | 7.79 | Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. ( Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N, 2013) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 7.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| " Hypoglycemia because of use of levofloxacin is a rarely reported complication." | 7.74 | Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period. ( Abraham, J; Jacob, JJ; Kapoor, R; Singh, M, 2008) |
| "Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients." | 7.71 | Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002) |
| "The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections." | 5.10 | [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003) |
| "The efficacy and safety of ofloxacin in the treatment of upper and lower urinary tract infections were studied with the drug use according to 4 regimens by comparison with nitrofurantoin in the treatment of lower urinary tract infections and trimethoprim/sulfamethoxazole in the treatment of upper urinary tract infections." | 5.08 | [Clinical experience with the use of ofloxacin in infections of the upper and lower urinary tracts: demonstrations of the results of clinical trials]. ( Liudvig, G, 1996) |
| "The efficacy and safety of a 3-day regimen of sparfloxacin were compared with those of a 3-day regimen of ofloxacin for the treatment of community-acquired acute uncomplicated urinary tract infections." | 5.08 | Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. ( Dorr, MB; Ellison, W; Henry, D; Magner, DJ; Mansfield, DL; Sullivan, J; Talbot, GH, 1998) |
| "In a prospective randomized study ofloxacin (400 mg orally once daily) versus co-trimoxazole (320/1,600 mg orally once daily) were given for 3 weeks in 30 and 22 elderly semimobile patients respectively, suffering from asymptomatic bacteriuria." | 5.07 | Kinetics and comparative efficacy of ofloxacin versus co-trimoxazole in the asymptomatic bacteriuria of elderly subjects. ( Dontas, A; Giamarellou, H; Iakovou, M; Petrikkos, G; Pistoni, M; Sfikakis, P, 1991) |
| "In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)." | 5.07 | Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. ( Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991) |
| "From 2009 to 2015, multi-bacillary leprosy cases at sentinel sites of 19 countries were studied for resistance to rifampicin, dapsone and ofloxacin by PCR sequencing of the drug-resistance-determining regions of the genes rpoB, folP1 and gyrA." | 3.88 | Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. ( Cambau, E; Cardona-Castro, N; Cauchoix, B; Cole, ST; Cooreman, EAWD; Gillini, L; Gupta, UD; Hagge, D; Hongseng, W; Indropo, A; Johnson, RC; Kai, M; Lavania, M; Matsuoka, M; Miyamoto, Y; Pannikar, VK; Pemmaraju, VRR; Rosa, PS; Saunderson, P; Srikantam, A; Suffys, P; Vissa, V; Williams, D, 2018) |
| " The objective is to determine the effect of application of topical ofloxacin on nasal and sinus mucosa in patients with proven existence of bacterial biofilms and persistent chronic sinusitis after FESS." | 3.81 | Effect of topical ofloxacin on bacterial biofilms in refractory post-sinus surgery rhino-sinusitis. ( Ezzat, WF; Fawaz, SA; Hamdy, TA; Rabie, H; Shokry, YA, 2015) |
| "It has been shown previously that fluoroquinolone resistance (defined by resistance to at least 2 mg/liter ofloxacin) has a different impact on moxifloxacin monotherapy depending on the mutation in the sole fluoroquinolone target in Mycobacterium tuberculosis, i." | 3.79 | Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. ( Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N, 2013) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 3.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| " Hypoglycemia because of use of levofloxacin is a rarely reported complication." | 3.74 | Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period. ( Abraham, J; Jacob, JJ; Kapoor, R; Singh, M, 2008) |
| " We report the first case of tendinitis after treatment with moxifloxacin, and of recurrent tendinitis after treatment with 2 different fluoroquinolones." | 3.72 | Recurrent tendinitis after treatment with two different fluoroquinolones. ( Burkhardt, O; Köhnlein, T; Pap, T; Welte, T, 2004) |
| "A systemic antibiotic, 1 g levofloxacin daily, had been started at the initial abscess operation." | 3.71 | [Osteomyelitis of the tibial head caused by Mycobacterium haemophilium in a patient with AIDS]. ( Brade, V; Enzensberger, R; Gruschke, A, 2002) |
| "Between 1989 and 1993, 136 multibacillary leprosy patients received a 6-week treatment regimen consisting of daily rifampicin 600 mg, ofloxacin 400 mg, clofazimine 100 mg and a weekly dose of 100 mg minocycline." | 3.71 | Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. ( Grillone, S; Pattyn, S, 2002) |
| "In this study, 72 men with nongonococcal urethritis were treated with levofloxacin." | 3.71 | Association of Mycoplasma genitalium persistence in the urethra with recurrence of nongonococcal urethritis. ( Deguchi, T; Ishiko, H; Kojima, K; Maeda, SI; Tamaki, M; Yasuda, M; Yoshida, T, 2001) |
| "Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients." | 3.71 | Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002) |
| "The effect of a single day treatment with 600 mg norfloxacin 600 mg ofloxacin or 1,920 mg trimethoprim-sulfamethoxazol was determined on 114 patients with acute cystitis." | 3.67 | [Single day treatment in acute cystitis]. ( Kawaguchi, K; Yamaguchi, K, 1988) |
| "Typhoid and paratyphoid (enteric fever) are febrile bacterial illnesses common in many low- and middle-income countries." | 2.82 | Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. ( Basnyat, B; Darton, TC; Eyre, D; Kuehn, R; Parry, CM; Stoesser, N, 2022) |
| "This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis." | 2.74 | Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ( Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009) |
| "No further relapse has been diagnosed since the beginning of retreatment." | 2.68 | High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. ( Grosset, JH; Jamet, P; Ji, B; Perani, EG; Sow, S; Traore, I, 1997) |
| "The case experienced pyothorax due to pulmonary tuberculosis three years before and Mycobacterium avium pleuritis one year before this episode." | 1.35 | [Case of pneumothorax associated with pulmonary Mycobacterium fortuitum infection]. ( Baba, T; Endo, T; Hagiwara, E; Komatsu, S; Matsumoto, Y; Nishihira, R; Ogura, T; Sato, T; Sekine, A; Shinohara, T; Sogo, Y; Takahashi, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.80) | 18.7374 |
| 1990's | 23 (29.11) | 18.2507 |
| 2000's | 34 (43.04) | 29.6817 |
| 2010's | 17 (21.52) | 24.3611 |
| 2020's | 2 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Kuehn, R | 3 |
| Stoesser, N | 3 |
| Eyre, D | 3 |
| Darton, TC | 3 |
| Basnyat, B | 3 |
| Parry, CM | 3 |
| Lazo-Porras, M | 1 |
| Prutsky, GJ | 1 |
| Barrionuevo, P | 1 |
| Tapia, JC | 1 |
| Ugarte-Gil, C | 1 |
| Ponce, OJ | 1 |
| Acuña-Villaorduña, A | 1 |
| Domecq, JP | 1 |
| De la Cruz-Luque, C | 1 |
| Prokop, LJ | 1 |
| Málaga, G | 1 |
| Cambau, E | 2 |
| Saunderson, P | 1 |
| Matsuoka, M | 1 |
| Cole, ST | 1 |
| Kai, M | 1 |
| Suffys, P | 1 |
| Rosa, PS | 1 |
| Williams, D | 1 |
| Gupta, UD | 1 |
| Lavania, M | 1 |
| Cardona-Castro, N | 2 |
| Miyamoto, Y | 1 |
| Hagge, D | 1 |
| Srikantam, A | 1 |
| Hongseng, W | 1 |
| Indropo, A | 1 |
| Vissa, V | 1 |
| Johnson, RC | 1 |
| Cauchoix, B | 1 |
| Pannikar, VK | 1 |
| Cooreman, EAWD | 1 |
| Pemmaraju, VRR | 1 |
| Gillini, L | 1 |
| Khasawneh, FA | 1 |
| Jou-Tindo, AJ | 1 |
| Woods, JL | 1 |
| Scurlock, AM | 1 |
| Hensel, DJ | 1 |
| Fillion, A | 1 |
| Aubry, A | 1 |
| Brossier, F | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 2 |
| Veziris, N | 1 |
| Ezzat, WF | 1 |
| Fawaz, SA | 1 |
| Rabie, H | 1 |
| Hamdy, TA | 1 |
| Shokry, YA | 1 |
| Beltrán-Alzate, C | 1 |
| López Díaz, F | 1 |
| Romero-Montoya, M | 1 |
| Sakamuri, R | 1 |
| Li, W | 1 |
| Kimura, M | 1 |
| Brennan, P | 1 |
| Béraud, G | 1 |
| Iba Ba, J | 1 |
| Legout, L | 1 |
| Senneville, E | 1 |
| Yazdanpanah, Y | 1 |
| Mouton, Y | 1 |
| Cox, HS | 1 |
| Sibilia, K | 1 |
| Feuerriegel, S | 1 |
| Kalon, S | 1 |
| Polonsky, J | 1 |
| Khamraev, AK | 1 |
| Rüsch-Gerdes, S | 1 |
| Mills, C | 1 |
| Niemann, S | 1 |
| Zhang, J | 1 |
| Xu, JF | 1 |
| Liu, YB | 1 |
| Xiao, ZK | 1 |
| Huang, JA | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Xia, QM | 1 |
| Wu, XJ | 1 |
| Cao, GY | 1 |
| Shi, YG | 1 |
| Zhang, YY | 1 |
| Blasi, F | 1 |
| Balagon, MF | 1 |
| Cellona, RV | 1 |
| Abalos, RM | 1 |
| Gelber, RH | 1 |
| Saunderson, PR | 1 |
| Han, JH | 1 |
| Nguyen, JC | 1 |
| Harada, S | 1 |
| Baddour, LM | 1 |
| Edelstein, PH | 1 |
| Li, Y | 1 |
| Huang, X | 1 |
| Yao, L | 1 |
| Shi, R | 1 |
| Zhang, G | 1 |
| Gaborieau, V | 1 |
| Weill, FX | 1 |
| Marchou, B | 1 |
| Wagenlehner, F | 1 |
| Roscher, K | 1 |
| Naber, KG | 1 |
| Girdhar, A | 1 |
| Kumar, A | 1 |
| Girdhar, BK | 1 |
| Lee, J | 2 |
| Lee, CH | 1 |
| Kim, DK | 1 |
| Yoon, HI | 1 |
| Kim, JY | 1 |
| Lee, SM | 1 |
| Yang, SC | 1 |
| Lee, JH | 1 |
| Yoo, CG | 1 |
| Lee, CT | 1 |
| Chung, HS | 1 |
| Kim, YW | 1 |
| Han, SK | 1 |
| Yim, JJ | 1 |
| Basu, PP | 1 |
| Rayapudi, K | 1 |
| Pacana, T | 1 |
| Shah, NJ | 1 |
| Krishnaswamy, N | 1 |
| Flynn, M | 1 |
| Shetty, VP | 2 |
| Wakade, AV | 2 |
| Ghate, SD | 1 |
| Pai, VV | 4 |
| Kumari, JO | 1 |
| Revankar, CR | 2 |
| Bulchand, HO | 3 |
| Ganapati, R | 3 |
| Zuck, P | 1 |
| Gruschke, A | 1 |
| Enzensberger, R | 1 |
| Brade, V | 1 |
| Pattyn, S | 1 |
| Grillone, S | 1 |
| Bello, S | 1 |
| Torres, A | 1 |
| Trinchieri, A | 1 |
| Marchetti, F | 1 |
| Schindler, C | 1 |
| Pittrow, D | 1 |
| Kirch, W | 1 |
| Kam, KM | 1 |
| Yip, CW | 1 |
| Burkhardt, O | 1 |
| Köhnlein, T | 1 |
| Pap, T | 1 |
| Welte, T | 1 |
| Soley, C | 1 |
| Arguedas, A | 1 |
| Porras, W | 1 |
| Guevara, S | 1 |
| Loaiza, C | 1 |
| Pérez, A | 1 |
| Rincón, G | 1 |
| Schultz, M | 1 |
| Arguedas, J | 1 |
| Brilla, R | 1 |
| Marone, P | 1 |
| Concia, E | 1 |
| Quarta, V | 1 |
| Minoli, L | 1 |
| Carnevale, G | 1 |
| Vogt, P | 1 |
| Schorn, T | 1 |
| Repp, H | 1 |
| Frei, U | 1 |
| Pichlmayr, R | 1 |
| Serra, AL | 1 |
| Klein, M | 1 |
| Nitsch, D | 1 |
| Dürr, D | 1 |
| Wermuth, B | 1 |
| Frey, FJ | 1 |
| Gabriels, P | 1 |
| Joosen, H | 1 |
| Put, E | 1 |
| Verhaegen, J | 1 |
| Magerman, K | 1 |
| Cartuyvels, R | 1 |
| De Benedetto, M | 1 |
| Salerni, L | 1 |
| De Benedetto, L | 1 |
| Passali, GC | 1 |
| Passali, D | 1 |
| Chiang, CY | 1 |
| Enarson, DA | 1 |
| Yu, MC | 1 |
| Bai, KJ | 1 |
| Huang, RM | 1 |
| Hsu, CJ | 1 |
| Suo, J | 1 |
| Lin, TP | 1 |
| Wormser, GP | 1 |
| Filozov, A | 1 |
| Telford, SR | 1 |
| Utpat, S | 1 |
| Kamer, RS | 1 |
| Liveris, D | 1 |
| Wang, G | 1 |
| Zentmaier, L | 1 |
| Schwartz, I | 1 |
| Aguero-Rosenfeld, ME | 1 |
| Ruiz-González, A | 1 |
| Giménez, A | 1 |
| Gómez-Arbonés, X | 1 |
| Soler-González, J | 1 |
| Sánchez, V | 1 |
| Falguera, M | 1 |
| Porcel, JM | 1 |
| Rivero, M | 1 |
| Otermin, I | 1 |
| Pereda, A | 1 |
| Cía, M | 1 |
| Martínez, M | 1 |
| Szklo, A | 1 |
| Mello, FC | 1 |
| Guerra, RL | 1 |
| Dorman, SE | 1 |
| Muzy-de-Souza, GR | 1 |
| Conde, MB | 1 |
| Singh, M | 1 |
| Jacob, JJ | 1 |
| Kapoor, R | 1 |
| Abraham, J | 1 |
| Hagiwara, E | 1 |
| Sekine, A | 1 |
| Sato, T | 1 |
| Baba, T | 1 |
| Shinohara, T | 1 |
| Endo, T | 1 |
| Sogo, Y | 1 |
| Nishihira, R | 1 |
| Komatsu, S | 1 |
| Matsumoto, Y | 1 |
| Ogura, T | 1 |
| Takahashi, H | 1 |
| Marlier, S | 1 |
| Carsuzaa, F | 1 |
| De Jaureguiberry, JP | 1 |
| Galzin, M | 1 |
| Carloz, E | 1 |
| Carli, P | 1 |
| Chagnon, A | 1 |
| Mühlberger, F | 1 |
| Nturanye, F | 1 |
| Nasbimana, J | 1 |
| Portaels, F | 1 |
| Pfau, A | 1 |
| Sacks, TG | 1 |
| Liudvig, G | 1 |
| Bruguera, M | 1 |
| Ji, B | 3 |
| Jamet, P | 1 |
| Sow, S | 1 |
| Perani, EG | 1 |
| Traore, I | 1 |
| Grosset, JH | 1 |
| Sehgal, VN | 1 |
| Kumar, S | 1 |
| Jain, S | 1 |
| Bhattacharya, SN | 1 |
| el-Sadr, WM | 1 |
| Perlman, DC | 1 |
| Matts, JP | 1 |
| Nelson, ET | 1 |
| Cohn, DL | 1 |
| Salomon, N | 1 |
| Olibrice, M | 1 |
| Medard, F | 1 |
| Chirgwin, KD | 1 |
| Mildvan, D | 1 |
| Jones, BE | 1 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Heifets, L | 1 |
| Hafner, R | 1 |
| Kingsley, S | 1 |
| Henry, D | 1 |
| Ellison, W | 1 |
| Sullivan, J | 1 |
| Mansfield, DL | 1 |
| Magner, DJ | 1 |
| Dorr, MB | 1 |
| Talbot, GH | 1 |
| Vila, J | 1 |
| Ruiz, J | 1 |
| Sanchez, F | 1 |
| Navarro, F | 1 |
| Mirelis, B | 1 |
| de Anta, MT | 1 |
| Prats, G | 1 |
| Ishida, Y | 1 |
| Ozaki, M | 1 |
| Picorini, L | 1 |
| Guglielmelli, E | 1 |
| Supiyaphun, P | 1 |
| Kerekhanjanarong, V | 1 |
| Koranasophonepun, J | 1 |
| Sastarasadhit, V | 1 |
| Yew, WW | 1 |
| Chan, CK | 1 |
| Chau, CH | 1 |
| Tam, CM | 1 |
| Leung, CC | 1 |
| Wong, PC | 1 |
| Tauro, S | 1 |
| Dobie, D | 1 |
| Richardson, G | 1 |
| Hastings, M | 1 |
| Mahendra, P | 1 |
| Del Pozo, JL | 1 |
| Lecároz, C | 1 |
| Hernáez, S | 1 |
| Leiva, J | 1 |
| Ballester, B | 1 |
| Antia, NH | 1 |
| Revenker, CR | 1 |
| Gupta, K | 1 |
| Hooton, TM | 1 |
| Roberts, PL | 1 |
| Stamm, WE | 1 |
| Maeda, SI | 1 |
| Tamaki, M | 1 |
| Kojima, K | 1 |
| Yoshida, T | 1 |
| Ishiko, H | 1 |
| Yasuda, M | 1 |
| Deguchi, T | 1 |
| Bonnafous, P | 1 |
| Perani, E | 1 |
| Sougakoff, W | 1 |
| Liassine, N | 1 |
| Chelfi, A | 1 |
| Rahal, K | 1 |
| Kumamoto, Y | 1 |
| Kulessa, W | 1 |
| Becker, EW | 1 |
| Berg, PA | 1 |
| Gentry, LO | 1 |
| Rodriguez-Gomez, G | 1 |
| Giamarellou, H | 1 |
| Iakovou, M | 1 |
| Pistoni, M | 1 |
| Petrikkos, G | 1 |
| Dontas, A | 1 |
| Sfikakis, P | 1 |
| Matsumoto, T | 1 |
| Kumazawa, J | 1 |
| Ueda, S | 1 |
| Eto, K | 1 |
| Yushita, Y | 1 |
| Saito, Y | 1 |
| Ishii, T | 1 |
| Sawae, Y | 1 |
| Khuri-Bulos, N | 1 |
| Shaker, K | 1 |
| Oksa, A | 1 |
| Dzúriková, V | 1 |
| Gajdos, M | 1 |
| Krechnáková, A | 1 |
| Krivosíková, G | 1 |
| Ploczeková, C | 1 |
| Spustová, V | 1 |
| Kiriushchenkov, AP | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial[NCT00734968] | Phase 4 | 161 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
The overall rate of UTI following the placement of sub-urethral sling for the treatment of stress urinary incontinence in our study was 24.8% (n = 37) (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
The incidence of UTI in the placebo group was 32%. (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
The incidence of UTI in the nitrofurantoin group was 17.6%. (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
8 reviews available for ofloxacin and Recrudescence
| Article | Year |
|---|---|
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Child; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Lepro | 2020 |
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross In | 2009 |
Relapsing Legionella pneumophila cellulitis: a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Cellulitis; Fatal Outcome; Female; Humans; Immunocompromi | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Re | 2010 |
Coexistence of rhinoscleroma with Rosai-Dorfman disease: is rhinoscleroma a cause of this disease?
Topics: Adult; Anti-Bacterial Agents; Biopsy; Emperipolesis; Female; Histiocytosis, Sinus; Humans; Klebsiell | 2012 |
[Rhinosinusitis: etiopathogenesis and antimicrobial therapy, an update].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria | 2006 |
[Treatment of chronic hepatitis C: still many problems pending].
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiv | 1997 |
18 trials available for ofloxacin and Recrudescence
| Article | Year |
|---|---|
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Co | 2009 |
The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Topics: Adult; Dapsone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; L | 2010 |
A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India.
Topics: Adolescent; Adult; Child; Child, Preschool; Clarithromycin; Female; Humans; India; Leprosy, Paucibac | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].
Topics: Anti-Infective Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Enterobacteriaceae | 2003 |
In vitro activities of levofloxacin and comparable agents against middle ear fluid, nasopharyngeal, and oropharyngeal pathogens obtained from Costa Rican children with recurrent otitis media or failing other antibiotic therapy.
Topics: Anti-Bacterial Agents; Child, Preschool; Costa Rica; Haemophilus influenzae; Humans; Infant; Levoflo | 2005 |
Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease.
Topics: Amoxicillin; Anti-Infective Agents; Cefuroxime; Clarithromycin; Female; Follow-Up Studies; Forced Ex | 2007 |
Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women.
Topics: Adult; Ciprofloxacin; Coitus; Female; Humans; Norfloxacin; Ofloxacin; Prospective Studies; Recurrenc | 1994 |
[Clinical experience with the use of ofloxacin in infections of the upper and lower urinary tracts: demonstrations of the results of clinical trials].
Topics: Anti-Infective Agents, Urinary; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 1996 |
High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks.
Topics: Adult; Anti-Infective Agents; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1997 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Fluo | 1998 |
Comparison of ofloxacin otic solution with oral amoxycillin plus chloramphenicol ear drop in treatment of chronic suppurative otitis media with acute exacerbation.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective | 2000 |
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women.
Topics: Adult; Algorithms; Anti-Infective Agents, Urinary; Feasibility Studies; Female; Follow-Up Studies; H | 2001 |
Single-dose treatment of female acute uncomplicated cystitis.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Cefixime; Cefotaxime; Clinical Protocols | 1992 |
Ofloxacin versus parenteral therapy for chronic osteomyelitis.
Topics: Administration, Oral; Adult; Aged; Cefazolin; Ceftazidime; Chronic Disease; Female; Gram-Negative Ba | 1991 |
Kinetics and comparative efficacy of ofloxacin versus co-trimoxazole in the asymptomatic bacteriuria of elderly subjects.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Bacteriuria; Female; Humans; Male; Ofloxacin; Prospective | 1991 |
Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside.
Topics: Administration, Oral; Adolescent; Aged; Bacteriuria; Drug Therapy, Combination; Gentamicins; Humans; | 1991 |
53 other studies available for ofloxacin and Recrudescence
| Article | Year |
|---|---|
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biopsy, Needle; Brazil; Colombia; Dapsone; DNA Gyrase; Dr | 2018 |
A 30-year-old woman with recurrent lower respiratory tract infections.
Topics: Adult; Anti-Bacterial Agents; Comorbidity; Diverticulum; Female; Humans; Ofloxacin; Radiography, Tho | 2013 |
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider.
Topics: Adolescent; Anti-Bacterial Agents; Arkansas; Ceftriaxone; Centers for Disease Control and Prevention | 2013 |
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Topics: Amikacin; Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Administration Schedule; D | 2013 |
Effect of topical ofloxacin on bacterial biofilms in refractory post-sinus surgery rhino-sinusitis.
Topics: Administration, Intranasal; Administration, Topical; Adult; Anti-Bacterial Agents; Biofilms; Case-Co | 2015 |
Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Proteins; Child; Colombia; Dapsone; DNA, Bacte | 2016 |
[Primary Salmonella vascular graft infection and conservative treatment].
Topics: Aged; Amikacin; Anti-Bacterial Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Blood Vessel Pr | 2008 |
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
Topics: Analysis of Variance; Antitubercular Agents; Cross Infection; Extensively Drug-Resistant Tuberculosi | 2008 |
[A case of Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin].
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2010 |
[Practice management of chronic bacterial prostatitis with levofloxacin].
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Chronic Disease; Escherichia coli | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Res | 2011 |
Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Topics: Academies and Institutes; Adult; Aged; Biomedical Research; Drug Therapy, Combination; Female; Follo | 2011 |
Single-dose ROM treatment for multilesion paucibacillary leprosy--further observations.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocyclin | 2002 |
[Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chron | 2002 |
[Osteomyelitis of the tibial head caused by Mycobacterium haemophilium in a patient with AIDS].
Topics: Abscess; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Clarit | 2002 |
Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
Topics: Belgium; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hu | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
[Fluoroquinolone superior to macrolide. Longer infection free period after acute bronchitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bronchitis; Clarithromycin; Doub | 2003 |
Reoccurrence of levofloxacin-induced tendinitis by phenoxymethylpenicillin therapy after 6 months: a rare complication of fluoroquinolone therapy?
Topics: Achilles Tendon; Adverse Drug Reaction Reporting Systems; Aged; Anti-Bacterial Agents; Arthritis; Dr | 2003 |
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Communicable Disease Control; Cycloserine; D | 2004 |
Recurrent tendinitis after treatment with two different fluoroquinolones.
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Asthma; Aza Compounds; Female; Fluoroquinolones; Human | 2004 |
Ofloxacin in the treatment of genito-urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Female Urogenital Disea | 1989 |
Experience with ofloxacin for short and long-term treatment of urinary tract infections in renal transplant recipients.
Topics: Follow-Up Studies; Humans; Kidney Transplantation; Ofloxacin; Postoperative Complications; Recurrenc | 1989 |
A puzzling case of high serum creatinine in a healthy woman.
Topics: Adult; Anti-Bacterial Agents; Creatinine; Drug Administration Schedule; False Positive Reactions; Fe | 2006 |
Recurrent Rhodococcus equi infection with fatal outcome in an immunocompetent patient.
Topics: Actinomycetales Infections; Aged; Brain Abscess; Fatal Outcome; Female; Humans; Immunocompetence; Mi | 2006 |
Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Drug Resis | 2006 |
Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
Topics: Aged; Anaplasma phagocytophilum; Anaplasmosis; Animals; Anti-Bacterial Agents; Disease Models, Anima | 2006 |
[Musculoskeletal adverse effects of levofloxacin].
Topics: Anti-Bacterial Agents; Arthralgia; Arthritis; Arthritis, Infectious; Arthroplasty, Replacement, Knee | 2006 |
Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury.
Topics: Antitubercular Agents; Brazil; Cohort Studies; Comorbidity; Confidence Intervals; Dose-Response Rela | 2007 |
Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fatal O | 2008 |
[Case of pneumothorax associated with pulmonary Mycobacterium fortuitum infection].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Combined Modality Therapy; Drainage; Drug Resistance, | 2008 |
[Recurrent lepromatous leprosy in conventional triple therapy: value of the rifampicin-ofloxacin combination].
Topics: Aged; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Ofloxacin; | 1995 |
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Cycloserine; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Relapse (reactivation) in borderline tuberculoid (BT) leprosy.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Dapsone; Drug Monitoring; Granuloma; Histiocyte | 1998 |
Relapse of multibacillary leprosy after rifampin and ofloxacin treatment for 28 days; a case report.
Topics: Adult; Drug Therapy, Combination; Humans; Leprosy; Male; Ofloxacin; Recurrence; Rifampin | 1998 |
Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.
Topics: Amino Acid Substitution; Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; F | 1999 |
Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
Topics: Anti-Infective Agents; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Ofloxacin; Re | 1998 |
National guideline for the management of non-gonococcal urethritis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases)
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chlortetracycline; | 1999 |
A recurrent case of BT leprosy with widely spread skin lesions showing a histopathology of indeterminate group after 4.5-years irregular treatment, Bangladesh.
Topics: Adult; Bangladesh; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy, Borderline; Lepro | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxac | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carm | 2000 |
[Recurrent abscesses in a renal transplant recipient].
Topics: Abscess; Drug Therapy, Combination; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney | 2001 |
Clinical, histopathological and bacteriological investigations in two cases of relapse following ROM treatment.
Topics: Adult; Animals; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Male; Mice; | 2001 |
Patient-initiated treatment of recurrent urinary tract infection in women.
Topics: Adult; Anti-Infective Agents, Urinary; Female; Follow-Up Studies; Humans; Middle Aged; Ofloxacin; Pa | 2001 |
Association of Mycoplasma genitalium persistence in the urethra with recurrence of nongonococcal urethritis.
Topics: Adolescent; Adult; Anti-Infective Agents, Urinary; DNA Primers; DNA, Bacterial; Humans; Levofloxacin | 2001 |
Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy.
Topics: Adult; Aged; Antibiotics, Antitubercular; Disease Models, Animal; DNA Gyrase; DNA-Directed RNA Polym | 2002 |
[Resistance to new quinolones among the enterobacteria].
Topics: Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Nalidixic Aci | 1992 |
[Recurrent agranulocytosis after taking calcium dobesilate].
Topics: Agranulocytosis; Calcium Dobesilate; Cefotaxime; Drug Hypersensitivity; Female; Humans; Lymphocyte A | 1992 |
Relapse of brucellosis following ofloxacin therapy.
Topics: Adolescent; Adult; Brucellosis; Female; Humans; Male; Ofloxacin; Prospective Studies; Recurrence | 1991 |
[Pefloxacin in the treatment of recurrent urinary tract infections].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Ofloxacin; Pefloxacin; Recurrence; Urinary Tract Inf | 1990 |
[Urogenital chlamydiosis].
Topics: Adult; Chlamydia Infections; Chronic Disease; Diagnosis, Differential; Female; Female Urogenital Dis | 1990 |
[Single day treatment in acute cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cystitis; | 1988 |